Primary Hyperparathyroidism
Conditions
Keywords
Primary Hyperparathyroidism
Brief summary
This is a research study to investigate cardiovascular health in people with mild hyperparathyroidism. Previous research has suggested that severe hyperparathyroidism may be associated with abnormalities in the heart and blood vessels. It is unclear whether mild hyperparathyroidism affects cardiovascular health. This study involves the investigation of the heart and blood vessels of people with mild hyperparathyroidism. Various non-invasive laboratory and radiological test to assess cardiovascular and bone health will be done at set intervals over the course of 2 years. It is our hypothesis that patients with primary hyperparathyroidism will have subtle abnormalities in their cardiovascular system. Using state-of-the art techniques that are sufficiently sensitive to detect these subtle abnormalities, we will define cardiovascular features of this disease that have, up to now, eluded clear definition. We expect taht the extent of these findings will be related to the severity of the underlying primary hyperparathyroidism. We further hypothesize that cardiovascular manifestations may regress with successful cure of the hyperparathyroid state.
Detailed description
This study involves a total of 4 visits over a 2-year period. A variety of tests to evaluate your cardiovascular and bone health are performed. The details and timing of the tests are explained below. VISIT #1 During the first visit, a research doctor or assistant explains the procedures in detail and answers questions. Blood is drawn (about 1-2 tablespoons) to confirm the diagnosis of hyperparathyroidism and get baseline blood values. VISIT #2-4 During the following visits, a variety of procedures are performed to evaluate cardiovascular and bone health. The details of the procedures and when they will be performed are outlined below. 1. Blood tests are performed at each visit. Approximately 1-2 tablespoons of blood will be drawn at each visit. 2. A 24-hour urine collection is done 3 times during the 2 year study. 3. Bone mineral density testing (known as DXA) is performed at baseline, 12 and 24 months after enrollment. 4. Carotid Ultrasound: At the baseline visit, 12 and 24 months after enrollment, carotid ultrasound is performed. 5. Echocardiogram: At the baseline visit, 12 and 24 months after enrollment, an echocardiogram is performed. 6. Endothelial Function: At baseline, 6 and 12 months after enrollment, flow mediated dilation of the brachial artery is performed.
Interventions
None listed
Sponsors
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Columbia University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
-Primary Hyperparathyroidism
Exclusion criteria
* Current use of oral bisphosphonates * Addition or change in cholesterol lowering medication * impaired renal function (creatinine \>2.0 mg/dl)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Structural evidence of increased vascular stiffness or cardiovascular calcification in patients with mild asymptomatic PHPT | 2 years | To determine whether or not there is structural evidence of increased vascular stiffness or cardiovascular calcification in patients with mild asymptomatic PHPT as compared to matched healthy controls, and to determine the reversibility of these manifestations after successful parathyroidectomy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evidence of abnormal cardiovascular function in patients with mild asymptomatic PHPT | 2 years | To determine whether or not there is evidence of abnormal cardiovascular function in patients with mild asymptomatic PHPT, and to determine the reversibility of these manifestations after successful parathyroidectomy |
| Evidence of abnormal cardiovascular structure or function in patients with asymptomatic PHPT who meet NIH Guidelines for Surgery | 2 years | To determine whether or not there is evidence of abnormal cardiovascular structure or function in patients with asymptomatic PHPT who meet NIH Guidelines for Surgery, and to determine the reversibility of these manifestations after successful parathyroidectomy |
Other
| Measure | Time frame | Description |
|---|---|---|
| To determine the association between the severity of PHPT and the presence of altered cardiovascular structure and function | 2 years | To determine the association between the severity of PHPT and the presence of altered cardiovascular structure and function as assessed in outcomes 1 to 3 |
Countries
United States
Outcome results
None listed